鲍曼不动杆菌
噬菌体疗法
屎肠球菌
抗生素耐药性
抗菌剂
铜绿假单胞菌
抗生素
微生物学
金黄色葡萄球菌
生物
医学
细菌
噬菌体
大肠杆菌
生物化学
遗传学
基因
作者
Rachel Yoon Kyung Chang,Sue C. Nang,Hak‐Kim Chan,Jian Li
标识
DOI:10.1016/j.addr.2022.114378
摘要
Antibiotic therapy has become increasingly ineffective against bacterial infections due to the rise of resistance. In particular, ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) have caused life-threatening infections in humans and represent a major global health threat due to a high degree of antibiotic resistance. To respond to this urgent call, novel strategies are urgently needed, such as bacteriophages (or phages), phage-encoded enzymes, immunomodulators and monoclonal antibodies. This review critically analyses these promising antimicrobial therapies for the treatment of multidrug-resistant bacterial infections. Recent advances in these novel therapeutic strategies are discussed, focusing on preclinical and clinical investigations, as well as combinatorial approaches. In this ‘Bad Bugs, No Drugs’ era, novel therapeutic strategies can play a key role in treating deadly infections and help extend the lifetime of antibiotics.
科研通智能强力驱动
Strongly Powered by AbleSci AI